Through you, Mr. Chair, to Dr. Lunney, as we had a conversation earlier, I won't speak to specific products, but the therapeutic class I know very well. I take two PPIs a day for a hiatus hernia, because they are avoiding an unnecessary and invasive surgical procedure that is 50% effective, not 100% effective.
In the context of coming back to my earlier testimony with respect to the changing safety profile of the medication, which is right at the heart of your question, I do not know of any studies that may or may not have been undertaken. Those questions would be best addressed to the member companies.
I do know as well, though, that C. difficile and MRSA, another of these hospital-borne and very antibiotic-resistant infections, are a key issue occupying health care institutions and health integration networks. Several of our member companies are pursuing vaccines.
Perhaps Keith could speak a little more to the science around that.